OTCPK:BIEL

Stock Analysis Report

Executive Summary

BioElectronics Corporation develops and markets disposable, drug-free, pain therapy, and wearable medical devices worldwide.

Snowflake

Fundamentals

Weak fundamentals or lack of information.

Risks

  • BioElectronics has significant price volatility in the past 3 months.
  • BioElectronics is not covered by any analysts.

Share Price & News

How has BioElectronics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-11.1%

BIEL

1.2%

US Medical Equipment

-0.6%

US Market


1 Year Return

-74.2%

BIEL

9.7%

US Medical Equipment

0.7%

US Market

BIEL underperformed the Medical Equipment industry which returned 9.9% over the past year.

BIEL underperformed the Market in United States of America which returned 0.7% over the past year.


Share holder returns

BIELIndustryMarket
7 Day-11.1%1.2%-0.6%
30 Day-11.1%3.5%4.9%
90 Day13.0%3.2%1.7%
1 Year-74.2%-74.2%10.6%9.7%3.0%0.7%
3 Year0%0%70.6%65.4%44.8%35.4%
5 Year-42.9%-42.9%139.4%112.2%62.0%44.3%

Price Volatility Vs. Market

How volatile is BioElectronics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is BioElectronics undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether BioElectronics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as BioElectronics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of BIEL’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through BioElectronics regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is BioElectronics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BioElectronics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of BIEL’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access BioElectronics's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has BioElectronics performed over the past 5 years?

1.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

BioElectronics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare BioElectronics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare BioElectronics's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if BioElectronics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if BioElectronics has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if BioElectronics improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.


Next Steps

Financial Health

How is BioElectronics's financial position?


Financial Position Analysis

BioElectronics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

BioElectronics's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

BioElectronics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if BioElectronics's debt level has increased considering it has negative shareholder equity.


Balance Sheet

High level of physical assets or inventory.

BioElectronics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

BioElectronics has less than a year of cash runway based on current free cash flow.

BioElectronics has less than a year of cash runway if free cash flow continues to reduce at historical rates of -14.3% each year.


Next Steps

Dividend

What is BioElectronics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate BioElectronics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate BioElectronics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as BioElectronics has not reported any payouts.

Unable to verify if BioElectronics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as BioElectronics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of BioElectronics's salary, the management and board of directors tenure and is there insider trading?

US$150k

CEO Compensation


CEO

Andrew Whelan (77yo)

0yrs

Tenure

US$150,000

Compensation

Mr. Andrew J. Whelan is the Founder of BioElectronics Corporation and serves as its Chief Executive Officer. Mr. Whelan has been the President of BioElectronics Corporation since April 2000. Mr. Whelan is  ...


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Andrew Whelan (77yo)

    Founder

    • Tenure: 0yrs
    • Compensation: US$150.00k
  • Ian Rawe

    Director of Clinical Research & Member of Medical Advisory Board

    • Tenure: 0yrs
  • Keith Nalepka (45yo)

    Vice President of Sales & Marketing

    • Tenure: 1.7yrs

Board Members

  • Lawrence Michaelis

    Chairman of Medical Advisory Board

    • Tenure: 0yrs
  • Andrew Whelan (77yo)

    Founder

    • Tenure: 0yrs
    • Compensation: US$150.00k
  • Kenneth McLeod

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Laurie Casas

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • William Van de Reis

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Ian Rawe

    Director of Clinical Research & Member of Medical Advisory Board

    • Tenure: 0yrs

Company Information

BioElectronics Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioElectronics Corporation
  • Ticker: BIEL
  • Exchange: OTCPK
  • Founded: 2000
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$17.958m
  • Shares outstanding: 22.45b
  • Website: https://www.bielcorp.com

Location

  • BioElectronics Corporation
  • 4539 Metropolitan Court
  • Frederick
  • Maryland
  • 21704
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BIELOTCPK (Pink Sheets LLC)YesCommon StockUSUSDApr 2004

Biography

BioElectronics Corporation develops and markets disposable, drug-free, pain therapy, and wearable medical devices worldwide. Its products include ActiPatch therapy for over-the-counter treatment of back pa ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/22 23:54
End of Day Share Price2019/09/20 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.